Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125567591 | 12556759 | 1 | I | 20160512 | 20160714 | 20160714 | EXP | US-GILEAD-2016-0214064 | GILEAD | 34.00 | YR | A | F | Y | 0.00000 | 20160714 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125567591 | 12556759 | 1 | PS | AMBRISENTAN | AMBRISENTAN | 1 | Unknown | 10 MG, UNK | 22081 | 10 | MG | TABLET | |||||||
| 125567591 | 12556759 | 2 | SS | REMODULIN | TREPROSTINIL | 1 | Subcutaneous | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125567591 | 12556759 | 1 | Product used for unknown indication |
| 125567591 | 12556759 | 2 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125567591 | 12556759 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125567591 | 12556759 | Activities of daily living impaired | |
| 125567591 | 12556759 | Cyst | |
| 125567591 | 12556759 | Fluid retention | |
| 125567591 | 12556759 | Infusion site infection | |
| 125567591 | 12556759 | Malaise |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125567591 | 12556759 | 1 | 20101201 | 0 |